Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CP-751,871 plus docetaxel/prednisone in hormone-insensitive prostate cancer
2005-002717-21Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of figitumumab in prostate cancer (PCa) (2 arms), sponsored by Pfizer. Primary endpoint: PSA Response Rate. Started Jul 2006; status: completed.
02
Drugs
figitumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-002717-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002717-21.